| Literature DB >> 35406452 |
Francesco Enrico D'Amico1,2, Claudia Mescoli3, Silvia Caregari1,2, Alessio Pasquale1,2, Ilaria Billato2, Remo Alessandris1,2, Jacopo Lanari1,2, Domenico Bassi2, Riccardo Boetto2, Francesco D'Amico2, Alessandro Vitale1,2, Sara Lonardi4, Enrico Gringeri1,2, Umberto Cillo1,2.
Abstract
In resected perihilar cholangiocarcinoma (PHC), positive ductal margin (DM) is associated with poor survival. There is currently little knowledge about the impact of positive radial margin (RM) when DM is negative. The aim of this study was to evaluate the incidence and the role of positive RM. Patients who underwent surgery between 2005 and 2017 where retrospectively reviewed and stratified according to margin positivity: an isolated RM-positive group and DM ± RM group. Of the 75 patients identified; 34 (45.3%) had R1 resection and 17 had positive RM alone. Survival was poorer in patients with R1 resection compared to R0 (p = 0.019). After stratification according to margin positivity; R0 patients showed better survival than DM ± RM-positive patients (p = 0.004; MST 43.9 vs. 23.6 months), but comparable to RM-positive patients (p = 0.361; MST 43.9 vs. 39.5 months). Recurrence was higher in DM ± RM group compared to R0 (p = 0.0017; median disease-free survival (DFS) 15 vs. 30 months); but comparable between RM and R0 group (p = 0.39; DFS 20 vs. 30 months). In univariate and multivariate analysis, DM positivity resulted as a negative prognostic factor both for survival and recurrence. In conclusion, positive RM resections appear to have different recurrence patterns and survival rates than positive DM resections.Entities:
Keywords: cholangiocarcinoma; extrahepatic bile duct; major hepatectomies; margin; perihilar cholangiocarcinoma; resection status
Year: 2022 PMID: 35406452 PMCID: PMC8996964 DOI: 10.3390/cancers14071680
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Patients’ characteristics and surgical procedures.
| R0 ( | RM ( | DM ± RM ( | Combined ( | ||
|---|---|---|---|---|---|
| Age, median (IQR) | 68.6 (62.7–75.6) | 63.5 (51.5–68.1) | 64.1 (60.3–66.7) | 65.7 (60.1–73.5) | 0.07 |
| Gender, male | 30 (73%) | 12 (71%) | 10 (59%) | 52 (69%) | 0.55 |
| Bilirubin (mg/dL), median (IQR) | 2.9 (1.0–6.2) | 2.1 (0.7–4.2) | 1.7 (1.1–5.5) | 2.5 (1–5.5) | 0.41 |
| CA19-9 (kU/L), median (IQR) | 108.0 (38.8–444.6) | 312.3 (42.1–1650.0) | 612.2 (250.8–2172.0) | 243.5 (44.7–1171.5) | 0.08 |
| CEA (ng/mL), median (IQR) | 2.9 (1.9–3.6) | 1.6 (1.2–2.5) | 2.2 (1.6–2.9) | 2.20 (1.5–3.5) | 0.24 |
| Pre-operative drain (PTBD or ERCP) | 23 (56%) | 12 (71%) | 13 (76%) | 48 (64%) | 0.28 |
| Bismuth type | 0.79 | ||||
| I | 1 (2.4%) | 1 (6.2%) | 0 (0%) | 2 (2.7%) | |
| II | 7 (17%) | 1 (6.2%) | 4 (24%) | 12 (16%) | |
| IIIa | 13 (32%) | 5 (31%) | 3 (18%) | 21 (28%) | |
| IIIb | 14 (34%) | 5 (31%) | 7 (41%) | 26 (35%) | |
| IV | 6 (15%) | 4 (25%) | 3 (18%) | 13 (18%) | |
| Surgical procedure | 0.68 | ||||
| Left hepatectomy ± S1 | 24 (59%) | 7 (41%) | 11 (65%) | 42 (56%) | |
| Right hepatectomy ± S1 | 12 (29%) | 7 (41%) | 3 (18%) | 22 (29%) | |
| Central hepatectomy ± S1 | 1 (2.4%) | 1 (5.9%) | 0 (0%) | 2 (2.7%) | |
| Isolated bile duct resection | 3 (7.3%) | 1 (5.9%) | 2 (12%) | 6 (8%) | |
| Others | 1 (2.4%) | 1 (5.9%) | 1 (5.9 %) | 3 (4%) | |
| Number of resected segments, | 4 (3–4) | 4 (4–4) | 4 (4–4) | 4 (3–4) | 0.66 |
| Vascular reconstruction | 8 (20%) | 6 (35%) | 1 (5.9%) | 15 (20%) | 0.11 |
| Adjuvant chemotherapy | 26 (63%) | 15 (88%) | 8 (47%) | 49 (65%) | 0.039 |
| Adjuvant radiotherapy | 7 (17%) | 8 (47%) | 1 (5.9%) | 16 (21.3%) | 0.010 |
Abbreviations: IQR, interquartile range; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; PTBD, percutaneous transhepatic biliary drainage; and ERCP, endoscopic retrograde cholangiopancreatography.
Pathologic features.
| R0 ( | RM ( | DM ± RM ( | Combined ( | ||
|---|---|---|---|---|---|
| Dimension (mm), | 30 (20–42.5) | 35 (30–40) | 40 (30–40) | 30 (22.5–40) | 0.37 |
| Grade, median (IQR) | 2 (2–2) | 2 (2–3) | 2 (2–2) | 2 (2–2) | 0.37 |
| Grade | 0.73 | ||||
| 1 | 6 (15%) | 1 (5.9%) | 1 (7.1%) | 8 (11%) | |
| 2 | 25 (64%) | 10 (59%) | 10 (71%) | 45 (64%) | |
| 3 | 8 (21%) | 6 (35%) | 3 (21%) | 17 (24%) | |
| T | 0.14 | ||||
| 1 | 6 (15%) | 0 (0%) | 1 (5.9%) | 7 (9.3%) | |
| 2a | 14 (34%) | 4 (24%) | 2 (12%) | 20 (27%) | |
| 2b | 16 (39%) | 13 (76%) | 11 (64.7%) | 40 (53.3%) | |
| 3 | 2 (4.9%) | 0 (0%) | 1 (5.9%) | 3 (4%) | |
| 4 | 2 (4.9%) | 0 (0%) | 2 (12%) | 4 (5.3%) | |
| x | 1 (2.4%) | 0 (0%) | 0 (0%) | 1 (1.3%) | |
| N | 0.52 | ||||
| 0 | 23 (56%) | 10 (59%) | 8 (47%) | 41 (55%) | |
| + | 15 (37%) | 4 (24%) | 8 (47%) | 27 (36%) | |
| x | 3 (7.3%) | 3 (18%) | 1 (5.9%) | 7 (9.3%) | |
| Stage | 0.16 | ||||
| I | 7 (17%) | 0 (0%) | 0 (0%) | 7 (9.3%) | |
| II | 16 (39%) | 13 (76%) | 7 (41%) | 36 (48%) | |
| IIIa | 1 (2%) | 0 (0%) | 0 (0%) | 1 (1%) | |
| IIIb | 3 (7%) | 0 (0%) | 2 (12%) | 5 (7%) | |
| IIIc | 10 (24%) | 4 (24%) | 6 (35%) | 20 (27%) | |
| IV | 4 (9.8%) | 0 (0%) | 2 (12%) | 6 (8%) | |
| Vascular invasion | 27 (71%) | 14 (82%) | 11 (69%) | 52 (73%) | 0.64 |
| Perineural invasion | 30 (81%) | 15 (88%) | 15 (94%) | 60 (86%) | 0.60 |
Abbreviations: IQR, interquartile range; T, tumour (8th AJCC TNM staging); and N, nodes (8th AJCC TNM staging).
Kaplan-Meier overall survival analysis.
| R0 | R1 | RM | DM ± RM | |
|---|---|---|---|---|
| 1 year | 92.7% | 76.4% | 82.4% | 70.1% |
| 3 years | 63.3% | 45.8% | 64.7% | 25.5% |
| 5 years | 40.5% | 15.3% | 24.3% | 6.4% |
| Median survival, months | 43.9 | 26.3 | 39.5 | 23.6 |
Figure 1Kaplan–Meier overall survival curves of R0 and R1 populations (log-rank test, p = 0.019).
Figure 2Kaplan-Meier overall survival curves of R0, RM, and DM ± RM populations (log-rank test, p = 0.0056).
Univariate analysis for survival prognostic factors.
| HR | L 95% CI | U 95% CI | ||
|---|---|---|---|---|
| RM | 1.39 | 0.69 | 2.79 | 0.358 |
| DM ± RM | 2.83 | 1.46 | 5.48 | 0.002 |
| CA19-9> 40 kU/L | 4.33 | 1.69 | 11.07 | 0.002 |
| N+ | 1.99 | 1.09 | 3.66 | 0.026 |
| Bismuth IV | 1.52 | 0.71 | 3.26 | 0.284 |
| Dimension | 1.00 | 0.99 | 1.02 | 0.545 |
| CT adj | 0.71 | 0.39 | 1.28 | 0.254 |
| Stage III–IV | 2.11 | 1.19 | 3.74 | 0.010 |
| G2 | 2.39 | 0.84 | 6.79 | 0.104 |
| G3 | 2.87 | 0.89 | 9.21 | 0.076 |
| Vascular Invasion | 2.17 | 1.04 | 4.52 | 0.038 |
| Complications | 3.94 | 1.40 | 11.04 | 0.009 |
| Recurrence | 14.78 | 3.57 | 61.23 | <0.001 |
Abbreviations: CA19-9, carbohydrate antigen 19-9; N+, lymphnode positivity; CT adj, adjuvant chemotherapy; and G2-3, tumour grading.
Multivariate analysis for survival prognostic factors.
| HR | L 95% CI | U 95% CI | ||
|---|---|---|---|---|
| RM | 1.65 | 0.69 | 3.92 | 0.259 |
| DM ± RM | 2.58 | 1.02 | 6.48 | 0.044 |
| CA19-9 | 4.30 | 1.20 | 15.38 | 0.024 |
| N+ | 1.24 | 0.57 | 2.70 | 0.584 |
| Bismuth IV | 5.92 | 1.87 | 18.73 | 0.002 |
| Vascular Invasion | 2.51 | 1.05 | 6.02 | 0.039 |
| Complications | 4.47 | 0.86 | 23.22 | 0.075 |
| Recurrence | 6.91 | 1.60 | 29.83 | 0.009 |
Abbreviations: CA19-9, carbohydrate antigen 19-9 and N+, lymphnode positivity.
Kaplan-Meier recurrence analysis.
| R0 | R1 | RM | DM ± RM | |
|---|---|---|---|---|
| 1 year | 17.9% | 37.2% | 35.3% | 39.1% |
| 3 years | 53.1% | 73.6% | 64.7% | 84.8% |
| 5 years | 65.6% | 86.4% | 73.5% | 100% |
| Median DFS, months | 30 | 16.3 | 20 | 15 |
Abbreviations: DFS, disease-free survival.
Figure 3Kaplan-Meier recurrence curves of R0, RM, and DM ± RM populations (log-rank test, p = 0.0066).
Univariate analysis for recurrence prognostic factors.
| HR | L 95% CI | U 95% CI | ||
|---|---|---|---|---|
| RM | 1.32 | 0.66 | 2.61 | 0.432 |
| DM ± RM | 2.72 | 1.39 | 5.34 | 0.004 |
| CA19-9 >40 kU/L | 2.44 | 1.13 | 5.28 | 0.023 |
| N+ | 1.52 | 0.84 | 2.76 | 0.169 |
| Bismuth IV | 1.50 | 0.73 | 3.10 | 0.274 |
| Dimension | 1.00 | 0.99 | 1.02 | 0.547 |
| CT adj | 0.97 | 0.54 | 1.76 | 0.925 |
| Stage III-IV | 1.51 | 0.86 | 2.68 | 0.154 |
| G2 | 1.28 | 0.52 | 3.11 | 0.592 |
| G3 | 1.67 | 0.61 | 4.55 | 0.317 |
| Vascular Invasion | 1.97 | 1.00 | 3.86 | 0.049 |
| Complications | 3.00 | 1.18 | 7.65 | 0.021 |
Abbreviations: CA19-9, carbohydrate antigen 19-9; N+, lymphnode positivity; CT adj, adjuvant chemotherapy; and G2-3, tumour grading.
Multivariate analysis for recurrence prognostic factors.
| HR | L 95% CI | U 95% CI | ||
|---|---|---|---|---|
| RM | 1.48 | 0.66 | 3.30 | 0.340 |
| DM ± RM | 2.95 | 1.30 | 6.69 | 0.009 |
| CA19-9 | 1.80 | 0.62 | 5.26 | 0.280 |
| N+ | 1.01 | 0.50 | 2.05 | 0.973 |
| Bismuth IV | 2.07 | 0.81 | 5.32 | 0.130 |
| Vascular Invasion | 1.75 | 0.80 | 3.85 | 0.162 |
| Complications | 4.20 | 1.08 | 16.43 | 0.039 |
Abbreviations: CA19-9, carbohydrate antigen 19-9 and N+, lymphnode positivity.